Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (3)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
Official source
Molnupiravir - LAGEVRIO capsules
Product / population
Adult COVID-19 EUA population; not FDA-approved labeling for unrestricted indications.
Renal measure
No renal adjustment; indexed eGFR is used for the PK evidence limitation
Before using this finding
Use the full EUA eligibility and duration rules. Do not interpret a brief institutional all-indications heading as unrestricted use.
Renal guidance and important limits
Limits that apply to these rows
Adult EUA treatment described: 800 mg orally every 12 hours for 5 days, begun within 5 days of symptoms, when alternatives are not accessible or clinically appropriate.
Not for patients under 18, prophylaxis or starting treatment for patients hospitalized because of COVID-19. Pregnancy, contraception and lactation counseling remain necessary.
The selected fact sheet says PK below eGFR 30 or on dialysis was not evaluated; lack of expected exposure change is not a completed dialysis study.
Molnupiravir - renal instruction
Renal population
Source-specific dose / instruction
Any degree of renal impairment
No renal dose adjustment recommended
Read the retained text before reformatting
Molnupiravir - renal instruction
Renal population
Source-specific dose / instruction
Any degree of renal impairment
No renal dose adjustment recommended
Adult EUA treatment described: 800 mg orally every 12 hours for 5 days, begun within 5 days of symptoms, when alternatives are not accessible or clinically appropriate.
Not for patients under 18, prophylaxis or starting treatment for patients hospitalized because of COVID-19. Pregnancy, contraception and lactation counseling remain necessary.
The selected fact sheet says PK below eGFR 30 or on dialysis was not evaluated; lack of expected exposure change is not a completed dialysis study.
Source revision: 6/2024 EUA fact sheet | Retrieved: 2026-09-10. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-specific interpretation
What the dialysis evidence actually supports
Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.
Molnupiravir - LAGEVRIO capsules
Authored v6.3; retrieved 2026-09-10 - retained source, not freshly reviewed in this release
These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.
Find text within this drug
Find a term without leaving this drug
Search the stored clinical text
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
source scope and renal guidance
Before use: Molnupiravir - LAGEVRIO capsules
UCSF prints >50 and <50, omitting exactly 50; the EUA renal instruction is not limited to those headings.
How to use this: Confirm the exact product, indication, renal measure and full source before prescribing.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source
Molnupiravir - LAGEVRIO capsules
Adult COVID-19 EUA population; not FDA-approved labeling for unrestricted indications.
Method: No renal adjustment; indexed eGFR is used for the PK evidence limitation
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Selected source sections stored locally. Not a complete monograph or independent clinical approval.
Renal guidance and important limits
Limits that apply to these rows
Adult EUA treatment described: 800 mg orally every 12 hours for 5 days, begun within 5 days of symptoms, when alternatives are not accessible or clinically appropriate.
Not for patients under 18, prophylaxis or starting treatment for patients hospitalized because of COVID-19. Pregnancy, contraception and lactation counseling remain necessary.
The selected fact sheet says PK below eGFR 30 or on dialysis was not evaluated; lack of expected exposure change is not a completed dialysis study.
Molnupiravir - renal instruction
Renal population
Source-specific dose / instruction
Any degree of renal impairment
No renal dose adjustment recommended
Read the retained text before reformatting
Molnupiravir - renal instruction
Renal population
Source-specific dose / instruction
Any degree of renal impairment
No renal dose adjustment recommended
Adult EUA treatment described: 800 mg orally every 12 hours for 5 days, begun within 5 days of symptoms, when alternatives are not accessible or clinically appropriate.
Not for patients under 18, prophylaxis or starting treatment for patients hospitalized because of COVID-19. Pregnancy, contraception and lactation counseling remain necessary.
The selected fact sheet says PK below eGFR 30 or on dialysis was not evaluated; lack of expected exposure change is not a completed dialysis study.
Adult EUA treatment described: 800 mg orally every 12 hours for 5 days, begun within 5 days of symptoms, when alternatives are not accessible or clinically appropriate.
Not for patients under 18, prophylaxis or starting treatment for patients hospitalized because of COVID-19. Pregnancy, contraception and lactation counseling remain necessary.
The selected fact sheet says PK below eGFR 30 or on dialysis was not evaluated; lack of expected exposure change is not a completed dialysis study.
GlobalRPh-hosted RX List · Adult COVID-19 EUA population; not FDA-approved labeling for unrestricted indications.
Renal method: No renal adjustment; indexed eGFR is used for the PK evidence limitation Source date: Revision not established in selected RX sections Retrieved: 2026-09-10
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
Use the full EUA eligibility and duration rules. Do not interpret a brief institutional all-indications heading as unrestricted use.
Selected source sections stored locally. Not a complete monograph or independent clinical approval.
Renal guidance and important limits
Limits that apply to these rows
Adult EUA treatment described: 800 mg orally every 12 hours for 5 days, begun within 5 days of symptoms, when alternatives are not accessible or clinically appropriate.
Not for patients under 18, prophylaxis or starting treatment for patients hospitalized because of COVID-19. Pregnancy, contraception and lactation counseling remain necessary.
The selected fact sheet says PK below eGFR 30 or on dialysis was not evaluated; lack of expected exposure change is not a completed dialysis study.
Molnupiravir - renal instruction
Renal population
Source-specific dose / instruction
Any degree of renal impairment
No renal dose adjustment recommended
Read the retained text before reformatting
Molnupiravir - renal instruction
Renal population
Source-specific dose / instruction
Any degree of renal impairment
No renal dose adjustment recommended
Adult EUA treatment described: 800 mg orally every 12 hours for 5 days, begun within 5 days of symptoms, when alternatives are not accessible or clinically appropriate.
Not for patients under 18, prophylaxis or starting treatment for patients hospitalized because of COVID-19. Pregnancy, contraception and lactation counseling remain necessary.
The selected fact sheet says PK below eGFR 30 or on dialysis was not evaluated; lack of expected exposure change is not a completed dialysis study.
Adult EUA treatment described: 800 mg orally every 12 hours for 5 days, begun within 5 days of symptoms, when alternatives are not accessible or clinically appropriate.
Not for patients under 18, prophylaxis or starting treatment for patients hospitalized because of COVID-19. Pregnancy, contraception and lactation counseling remain necessary.
The selected fact sheet says PK below eGFR 30 or on dialysis was not evaluated; lack of expected exposure change is not a completed dialysis study.
Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.